Chronic inflammation disease biotech company Evommune (EVMN.US) applies for US stock market IPO, aiming to raise $100 million.

Focused on developing therapies for chronic inflammatory diseases, the biotechnology company Evommune (EVMN.US) in the 2nd phase of research and development submitted an application to the U.S. Securities and Exchange Commission (SEC) on Thursday, planning to raise up to $100 million in funds through an initial public offering (IPO). It is understood that Evommune's core candidate drug EVO756 is a potent and highly selective oral small molecule MRGPRX2 antagonist, used to treat chronic spontaneous urticaria (CSU) and atopic dermatitis (AD). Another drug in development by the company is EV0301, a long-acting fusion protein composed of the IL-18 binding protein and the anti-serum albumin Fab-related structure domain, which is suitable for the treatment of atopic dermatitis (AD) and ulcerative colitis (UC). Currently, Evommune has initiated phase 2b clinical trials of EVO756, with trial results expected to be announced in the second half of 2026; while plans are also in place to initiate phase 2 clinical trials for moderate to severe ulcerative colitis (UC) patients in 2026. Founded in 2020 and headquartered in Palo Alto, California, the company reported revenue of $3 million in the 12 months ending June 30, 2025. The company plans to list on the New York Stock Exchange under the ticker symbol EVMN. Previously, Evommune had submitted an IPO application in confidence on May 14, 2025. The joint bookrunners for this transaction include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald, with pricing terms yet to be disclosed.